Table 5 The combined synergizing effects of Gossypol and its derivative (AT-101) against certain cancers and cell types
Mimetic | Cancer | Cell Type | Combined | Apoptosis | Ref |
|---|---|---|---|---|---|
Gossypol | Glioblastoma | Diff13–20, TS13–20 | temozolomide resistance | – | [180] |
Gossypol | CML | K562 | imatinib | – | [181] |
Gossypol | Colon | HT-29 cells, HCT116, RKO | fluorouracil | – | [182] |
Gossypol | Nasopharyngeal, Breast, Gastric | MCF-7, YC116, CNE2 | gemcitabine | – | [183] |
Gossypol | Ovarian | OVCAR-3 and MDAH-2774 | zoledronic acid | – | [184] |
Gossypol | Thoracic | H460, TE2, H211 | TRAIL | – | [185] |
AT-101 | Bladder | UM-UC2, UM-UC9 | gemcitabine, carboplatin | synergized | [167] |
AT-101 | Breast | SKBR-3, MDA-MB-453 | trastuzumab | – | [186] |
AT-101 | Pancreatic | BxPC-3 | genistein | – | [187] |
AT-101 | Prostate | PC-3 and xenograft | radiation | – | [188] |
AT-101 | Prostate | PC-3 xenograft | docetaxel | synergized | [170] |
AT-101 | Prostate | DU145, PC-3 | sorafenib | – | [174] |
AT-101 | Prostate | VCaP | bicalutamide | – | [189] |